Genenta Science posts H1 2025 financial results

Genenta Science S.p.A. filed a Form 6-K to provide its unaudited consolidated financial statements as of June 30, 2025 and for the six months ended June 30, 2025.

Rhea-AI Filing Summary

Genenta Science S.p.A. filed a Form 6-K to provide its unaudited consolidated financial statements as of June 30, 2025 and for the six months ended June 30, 2025. These interim results give a mid-year view of the company’s financial position and performance.

The filing also includes Management’s Discussion and Analysis of Financial Condition and Results of Operations for the same six-month period, offering management’s narrative on the numbers. The Form 6-K is incorporated by reference into Genenta’s existing shelf registration statement on Form F-3, linking these updated financials to potential future securities offerings.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What period does Genenta Science (GNTA) cover in this Form 6-K?

The Form 6-K covers Genenta Science’s unaudited consolidated financial statements as of June 30, 2025 and for the six months ended June 30, 2025, providing a mid-year update on financial condition and operating results.

What financial documents are included in Genenta Science (GNTA) October 2025 Form 6-K?

The filing includes unaudited consolidated financial statements, consolidated balance sheets, statements of operations and comprehensive loss, changes in shareholders’ equity, cash flows, and accompanying notes, all for the six months ended June 30, 2025, plus related management discussion and analysis.

Is Genenta Science’s (GNTA) June 30, 2025 financial information audited?

No, the financial statements provided are unaudited consolidated financial statements as of June 30, 2025 and for the six months ended June 30, 2025, meaning they have not undergone a full external audit, but still follow required reporting standards.

How is this Genenta Science (GNTA) Form 6-K related to its Form F-3 shelf registration?

The Form 6-K is expressly incorporated by reference into Genenta Science’s Form F-3 shelf registration statement, allowing these June 30, 2025 interim financials and related disclosures to form part of the information base supporting potential future securities offerings.

What analysis accompanies Genenta Science’s (GNTA) June 30, 2025 financial statements?

Alongside the unaudited financial statements, Genenta provides Management’s Discussion and Analysis of Financial Condition and Results of Operations, giving management’s commentary on performance, liquidity, and key factors affecting the six months ended June 30, 2025.

In what format is Genenta Science (GNTA) providing its 2025 interim financial data?

Genenta supplies its interim financial data both as traditional unaudited consolidated financial statements and in Inline XBRL format, covering balance sheets, operations and comprehensive loss, equity changes, cash flows, and notes, enhancing electronic analysis and regulatory compliance.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/10/2025 - 04:06 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the month of October 2025

Commission File Number: 001-41115

GENENTA SCIENCE S.P.A.

(Translation of Registrant’s Name into English)

Via Olgettina No. 58

20132 Milan, Italy

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

This report on Form 6-K is incorporated by reference into the registrant’s registration statement on Form F-3 (File No. 333-271901).

Genenta Science S.p.A. Reports Financial Results for the Six Months Ended June 30, 2025

Genenta Science S.p.A. (“Genenta”) is furnishing this report on Form 6-K to provide its unaudited consolidated financial statements as of June 30, 2025, and for the six months ended June 30, 2025, and to provide its Management’s Discussion and Analysis of Financial Condition and Results of Operations with respect to such financial statements.

The unaudited consolidated financial statements as of June 30, 2025, and for the six months ended June 30, 2025, are attached to this Form 6-K as Exhibit 99.1. Management’s Discussion and Analysis of Financial Condition and Results of Operations is attached to this Form 6-K as Exhibit 99.2.

EXHIBIT INDEX

Exhibit		Title
99.1		Unaudited Consolidated Financial Statements as of June 30, 2025, and for the six months ended June 30, 2025.
99.2		Management’s Discussion and Analysis of Financial Condition and Results of Operations.
101		The following materials from Genenta’s Report on Form 6-K for the six months ended June 30, 2025, formatted in Inline XBRL (eXtensible Business Reporting Language): (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements of Operations and Comprehensive Loss, (iii) the Consolidated Statements of Changes in Shareholders’ Equity, (iv) the Consolidated Statements of Cash Flows, and (v) Notes to the Consolidated Financial Statements.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	GENENTA SCIENCE S.P.A.
Date: October 10, 2025	By:	/s/ Richard B. Slansky
		Richard B. Slansky, Chief Financial Officer